Afficher la notice abrégée

Impact of a population-based asthma management program in France (Sophia Asthme): A matched controlled before-and-after quasi-experimental study using the French health insurance database (SNDS)

dc.rights.licenseopenen_US
dc.contributor.authorDIB, F.
dc.contributor.authorDE RYCKE, Y.
dc.contributor.authorGUILLO, S.
dc.contributor.authorLAFOURCADE, A.
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorRAHERISON-SEMJEN, Chantal
dc.contributor.authorTAILLE, C.
dc.contributor.authorTUBACH, F.
dc.date.accessioned2020-06-05T10:04:18Z
dc.date.available2020-06-05T10:04:18Z
dc.date.issued2019-08
dc.identifier.issn1099-1557 (Electronic) 1053-8569 (Linking)en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/7765
dc.description.abstractEnPURPOSE: Sophia Asthme (SA) is a chronic disease management program of the French national health insurance for adult patients with asthma. We evaluated the early impact of this intervention. METHODS: We conducted a matched controlled, before-and-after quasi-experimental study within the French Health Insurance Database (Systeme National Des Donnees de Sante [SNDS]). The SA program was implemented in a set of 18 Departements in France and targeted 18- to 44-year-old subjects, with at least two reimbursement dates for asthma drug therapy during the 12-month period prior to program targeting. Change in outcomes was assessed from the "before program" period (January-December 2014) to the "after program implementation" period (March 2015-February 2016) in the program group (eligible to SA program in the 18 Departements) and in the matched controlled group. The main outcome measure was the before-after change in proportion of subjects with a controllers/(controllers+relievers) ratio greater than 50%. RESULTS: Of the 99 578 subjects of the program group, 9225 (9.3%) actually participated in SA program. The program had no significant impact on the proportion of subjects with a ratio greater than 50%. However, subjects exposed to SA program were significantly more likely to be dispensed controller medications (OR = 1.04; 95% CI, 1.01-1.07) and to sustain their use of these medications (OR = 1.08; 95% CI, 1.05-1.12). CONCLUSION: We did not demonstrate any significant impact of the program on the primary outcome. The modest yet encouraging findings of this early evaluation suggest the need for reformulation of the program and its evaluation.
dc.language.isoENen_US
dc.subject.enEPICENE
dc.title.enImpact of a population-based asthma management program in France (Sophia Asthme): A matched controlled before-and-after quasi-experimental study using the French health insurance database (SNDS)
dc.title.alternativePharmacoepidemiol Drug Safen_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1002/pds.4842en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed31237054en_US
bordeaux.journalPharmacoepidemiol Drug Safen_US
bordeaux.page1097-1108en_US
bordeaux.volume28en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.issue8en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.teamEPICENE_BPH
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.exportfalse
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Pharmacoepidemiol%20Drug%20Saf&rft.date=2019-08&rft.volume=28&rft.issue=8&rft.spage=1097-1108&rft.epage=1097-1108&rft.eissn=1099-1557%20(Electronic)%201053-8569%20(Linking)&rft.issn=1099-1557%20(Electronic)%201053-8569%20(Linking)&rft.au=DIB,%20F.&DE%20RYCKE,%20Y.&GUILLO,%20S.&LAFOURCADE,%20A.&RAHERISON-SEMJEN,%20Chantal&rft.genre=article


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée